Thanks to your valuable input and collaboration, JPT was among the very first companies responding to the COVID-19 pandemic. Starting in January 2020, our R&D teams designed the first SARS-CoV-2 specific peptide tools which we launched just 8 weeks later.
As of now, our comprehensive portfolio of products ranges from a large selection of off-the-shelf catalog products covering the entire SARS-CoV-2 genome to clinical grade peptides currently being used in accompanying the most advanced COVID-19 vaccination trials.
For an overview of all the new SARS-CoV-2 related peptide products and services please have a look at our new SARS-CoV-2 flyer and our SARS-CoV-2 webpage.
The quality of these products is continuously validated by numerous high impact contributions in highly ranked and cited papers.
Here are just a few of them:
“Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors”
Braun et al, Nature (2020)
"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice"
McKay et al, Nature 2020
"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques"
Mercado et al., Nature (2020)
“Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing”
Zecha et al, Mol Cell Proteomics (2020)
"An mRNA Vaccine against SARS-CoV-2 — Preliminary Report"
Jackson et al, New England J of Med (2020)
"SARS-CoV-2-reactive interferon‐γ‐producing CD8+ T cells in patients hospitalized with Coronavirus Disease 2019"
Giminez et al, J Med Vir (2020)
"Concurrent human antibody and TH1 type T-cell responses 2 elicited by a COVID-19 RNA vaccine"
Sahin et al, medRXiv (2020)
“Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates”
Corbett et al. New England J of Med (2020)
We welcome your additional references! Please send us the citation for your contribution and we will be happy to give them appropriate visibility in one of our next releases.